Abstract
Tumor-infiltrating lymphocytes (TIL) are an important component of the tumor environment. Their role in tumor growth and progression has been debated for decades. Today, emphasis has shifted to beneficial effects of TIL for the host and to therapies optimizing the benefits by reducing immune suppression in the tumor microenvironment. Evidence indicates that when TILs are present in the tumor as dense aggregates of activated immune cells, tumor prognosis and responses to therapy are favorable. Gene signatures and protein profiling of TIL at the population and single-cell levels provide clues not only about their phenotype and numbers but also about TIL potential functions in the tumor. Correlations of the TIL data with clinicopathological tumor characteristics, clinical outcome, and patients’ survival indicate that TILs exert influence on the disease progression, especially in colorectal carcinomas and breast cancer. At the same time, the recognition that TIL signatures vary with time and cancer progression has initiated investigations of TIL as potential prognostic biomarkers. Multiple mechanisms are utilized by tumors to subvert the host immune system. The balance between pro- and antitumor responses of TIL largely depends on the tumor microenvironment, which is unique in each cancer patient. This balance is orchestrated by the tumor and thus is shifted toward the promotion of tumor growth. Changes occurring in TIL during tumor progression appear to serve as a measure of tumor aggressiveness and potentially provide a key to selecting therapeutic strategies and inform about prognosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- CTL:
-
Cytolytic T cell
- CTLA-4:
-
Cytotoxic T lymphocyte-associated antigen-4
- DC:
-
Dendritic cells
- EVs:
-
Extracellular vesicles
- ICIs:
-
Immune checkpoint inhibitors
- IFN-Îł:
-
Interferon Îł
- IGKC:
-
IgG kappa chain
- IL:
-
Interleukin
- MHC:
-
Major histocompatibility complex
- NK:
-
Natural killer cells
- NKG2D:
-
nk2G gene
- NSCLC:
-
Nonsmall cell lung cancer
- PD-1:
-
Programmed cell death protein-1
- TAA:
-
Tumor-associated antigen
- TCR:
-
T-cell receptor
- TGF-β:
-
Transforming growth factor-β
- Th :
-
T helper cell
- TIL:
-
Tumor-infiltrating lymphocytes
- TME:
-
Tumor microenvironment
- Treg:
-
Regulatory T cells
References
Allen BM, Hiam KJ, Burnett CE, Venida A, DeBarge R, Tenvooren I, Marquez DM, Cho NW, Carmi Y, Spitzer MH (2020) Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med 26(7):1125–1134. https://doi.org/10.1038/s41591-020-0892-6
Biragyn A, Lee-Chang C (2012) A new paradigm for an old story: the role of regulatory B cells in cancer. Front Immunol 3:206. https://doi.org/10.3389/fimmu.2012.00206
Bracci L, Fragale A, Gabriele L, Moschella F (2020) Towards a systems immunology approach to unravel responses to Cancer immunotherapy. Front Immunol 11:582744. https://doi.org/10.3389/fimmu.2020.582744
Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM (2011) Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 60(1):15–22. https://doi.org/10.1007/s00262-010-0940-z
Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, Blanchard T, McMahon D, Sidney J, Sette A, Baker BM, Mandoiu II, Srivastava PK (2014) Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 211(11):2231–2248. https://doi.org/10.1084/jem.20141308
Ferrone S, Whiteside TL (2007) Tumor microenvironment and immune escape. Surg Oncol Clin N Am 16(4):755–774 viii. https://doi.org/10.1016/j.soc.2007.08.004
Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7(5):1016–1036
Fregni G, Perier A, Avril MF, Caignard A (2012) NK cells sense tumors, course of disease and treatments: consequences for NK-based therapies. Onco Targets Ther 1(1):38–47. https://doi.org/10.4161/onci.1.1.18312
Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA (2017) The broad Spectrum of human natural killer cell diversity. Immunity 47(5):820–833. https://doi.org/10.1016/j.immuni.2017.10.008
Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pages F, Tartour E, Sautes-Fridman C (2011) Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 344:1–24. https://doi.org/10.1007/82_2010_46
Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14(12):717–734. https://doi.org/10.1038/nrclinonc.2017.101
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. https://doi.org/10.1126/science.1129139
Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA (2012) The immune score as a new possible approach for the classification of cancer. J Transl Med 10:1. https://doi.org/10.1186/1479-5876-10-1
Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F (2014) Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 232(2):199–209. https://doi.org/10.1002/path.4287
Giraldo NA, Becht E, Remark R, Damotte D, Sautes-Fridman C, Fridman WH (2014) The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 27:8–15. https://doi.org/10.1016/j.coi.2014.01.001
Giraldo NA, Peske JD, Sautes-Fridman C, Fridman WH (2019) Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch 474(4):463–474. https://doi.org/10.1007/s00428-018-02517-1
Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V (2019) Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer 120(1):16–25. https://doi.org/10.1038/s41416-018-0333-1
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden G, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, Andre F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international Immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further Research. Adv Anat Pathol 24(5):235–251. https://doi.org/10.1097/PAP.0000000000000162
Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165(1):35–44. https://doi.org/10.1016/j.cell.2016.02.065
Jacquelot N, Tellier J, Nutt Sl BG (2021) Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. Onco Targets Ther 10(1):1900508. https://doi.org/10.1080/2162402X.2021.1900508
Kalams SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188(12):2199–2204. https://doi.org/10.1084/jem.188.12.2199
Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54(8):721–728. https://doi.org/10.1007/s00262-004-0653-2
Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6):1141–1149. https://doi.org/10.1182/blood-2009-03-208249
Lanca T, Silva-Santos B (2012) The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Onco Targets Ther 1(5):717–725. https://doi.org/10.4161/onci.20068
Linette GP, Carreno BM (2019) Tumor-infiltrating lymphocytes in the checkpoint inhibitor era. Curr Hematol Malig Rep 14(4):286–291. https://doi.org/10.1007/s11899-019-00523-x
Lucca LE, Axisa PP, Lu B, Harnett B, Jessel S, Zhang L, Raddassi K, Zhang L, Olino K, Clune J, Singer M, Kluger HM, Hafler DA (2021) Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. J Exp Med 218(4). https://doi.org/10.1084/jem.20200921
Maby P, Corneau A, Galon J (2020) Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF). Methods Enzymol 632:339–368. https://doi.org/10.1016/bs.mie.2019.07.025
Marar C, Starich B, Wirtz D (2021) Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol 22(5):560–570. https://doi.org/10.1038/s41590-021-00899-0
Melaiu O, Lucarini V, Cifaldi L, Fruci D (2019) Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol 10:3038. https://doi.org/10.3389/fimmu.2019.03038
Mittendorf EA, Sharma P (2010) Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines 9(1):89–105. https://doi.org/10.1586/erv.09.144
Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618. https://doi.org/10.1200/JCO.2010.30.5425
Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH (2012) CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12):3281–3292. https://doi.org/10.1158/1078-0432.CCR-12-0234
Okla K, Farber DL, Zou W (2021) Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med 218(4). https://doi.org/10.1084/jem.20201605
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, Andre P, Dieu-Nosjean MC, Alifano M, Regnard JF, Fridman WH, Sautes-Fridman C, Cremer I (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422. https://doi.org/10.1158/0008-5472.CAN-10-4179
Robins H (2013) Immunosequencing: applications of immune repertoire deep sequencing. Curr Opin Immunol 25(5):646–652. https://doi.org/10.1016/j.coi.2013.09.017
Romagnani S (1997) The Th1/Th2 paradigm. Immunol Today 18(6):263–266. https://doi.org/10.1016/s0167-5699(97)80019-9
Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19(6):307–325. https://doi.org/10.1038/s41568-019-0144-6
Saze Z, Schuler PJ, Hong CS, Cheng D, Jackson EK, Whiteside TL (2013) Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 122(1):9–18. https://doi.org/10.1182/blood-2013-02-482406
Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405–5413. https://doi.org/10.1158/0008-5472.CAN-07-5206
Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Muller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenfuhrer J, Hengstler JG (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18(9):2695–2703. https://doi.org/10.1158/1078-0432.CCR-11-2210
Silva-Santos B (2010) Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur J Immunol 40(7):1873–1876. https://doi.org/10.1002/eji.201040707
Snyder A, Chan TA (2015) Immunogenic peptide discovery in cancer genomes. Curr Opin Genet Dev 30:7–16. https://doi.org/10.1016/j.gde.2014.12.003
Strickler JH, Hanks BA, Khasraw M (2021) Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res 27(5):1236–1241. https://doi.org/10.1158/1078-0432.CCR-20-3054
Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196(5):619–628. https://doi.org/10.1084/jem.20012142
Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, Caldas C (2010) Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 10:604. https://doi.org/10.1186/1471-2407-10-604
Thommen DS, Schumacher TN (2018) T cell dysfunction in Cancer. Cancer Cell 33(4):547–562. https://doi.org/10.1016/j.ccell.2018.03.012
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research N, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I (2018) The immune landscape of Cancer. Immunity 48(4):812–830 e814. https://doi.org/10.1016/j.immuni.2018.03.023
Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jane-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352(6282):189–196. https://doi.org/10.1126/science.aad0501
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207–211. https://doi.org/10.1126/science.aad0095
Van den Eynde M, Mlecnik B, Bindea G, Fredriksen T, Church SE, Lafontaine L, Haicheur N, Marliot F, Angelova M, Vasaturo A, Bruni D, Jouret-Mourin A, Baldin P, Huyghe N, Haustermans K, Debucquoy A, Van Cutsem E, Gigot JF, Hubert C, Kartheuser A, Remue C, Leonard D, Valge-Archer V, Pages F, Machiels JP, Galon J (2018) The link between the multiverse of immune microenvironments in metastases and the survival of colorectal Cancer patients. Cancer Cell 34(6):1012–1026 e1013. https://doi.org/10.1016/j.ccell.2018.11.003
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44–49. https://doi.org/10.1126/science.1198687
Wang L, Wang Y, Chang Q (2016) Feature selection methods for big data bioinformatics: a survey from the search perspective. Methods 111:21–31. https://doi.org/10.1016/j.ymeth.2016.08.014
Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM (2021) Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591(7851):645–651. https://doi.org/10.1038/s41586-020-03045-2
Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45):5904–5912. https://doi.org/10.1038/onc.2008.271
Whiteside TL (2010) Immune responses to malignancies. J Allergy Clin Immunol 125(2 Suppl 2):S272–S283. https://doi.org/10.1016/j.jaci.2009.09.045
Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22(4):327–334. https://doi.org/10.1016/j.semcancer.2012.03.004
Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41(1):245–251. https://doi.org/10.1042/BST20120265
Whiteside TL, Ferrone S (2012) For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res 18(9):2417–2419. https://doi.org/10.1158/1078-0432.CCR-12-0566
Whiteside TL, Schuler P, Schilling B (2012) Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 12(10):1383–1397. https://doi.org/10.1517/14712598.2012.707184
Wu FXM, Hun M, She Z, Li C, Luo S, Chen X, Wan W, Wen C, Tian J (2021) Natural killer cell-derived extracellular vesicles: novel players in Cancer immunotherapy. Front Immunol. https://doi.org/10.3389/fimmu.2021.658698
Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515(7528):572–576. https://doi.org/10.1038/nature14001
Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B (2012) Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys 62(1):153–159. https://doi.org/10.1007/s12013-011-9276-3
Zhu J, Paul WE (2010) Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 238(1):247–262. https://doi.org/10.1111/j.1600-065X.2010.00951.x
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Whiteside, T.L. (2022). Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. In: Klink, M., Szulc-Kielbik, I. (eds) Interaction of Immune and Cancer Cells. Experientia Supplementum, vol 113. Springer, Cham. https://doi.org/10.1007/978-3-030-91311-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-91311-3_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-91310-6
Online ISBN: 978-3-030-91311-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)